Titus, yeah I had my sights on QRX also, you can't be everywhere and good on Mattkid he puts in some good yards of research, I've had a good run on LNC lately and am ready to get in on others now hence me lurking here.
Hey Aggie62, good old ACL hey!! Luckily I only hold a few of those, when a CEO can't give definite answers to simple questions it's always time to cut and run. I understand what you are saying with the patent timing, though this is out of the company's control when a decision is to be made.
Robert Calnon from Eureka Report wrote:
"I also noted another biotech Acrux (ACR: ASX) at the same time, and while its performance to date has been disappointing (around minus 10%), there a couple of important catalysts on the horizon which could see the share price improve. Over the coming weeks, investors should be looking for the US sales data for its key product, Axiron, and also the outcome of its US patent extension application (in late January)"
GL all.........
ACR Price at posting:
$2.93 Sentiment: LT Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)